TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14615442

Group type: EXPERIMENTAL
Intervention: Audiotaped consultation (patients given audiotape)
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Audiotaped consultation (patients offered choice of receiving audiotape or not)
Number of subjects: 628

Group type: COMPARATOR
Intervention: Audiotaped consultation (not audiotaped)
Number of subjects: 628

Group type: COMPARATOR
Intervention: Audiotaped consultation (no audiotape given)
Number of subjects: 628
Study: 9831777

Group type: EXPERIMENTAL
Intervention: 0.05% NaF
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 40% xylitol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.025% NaF plus 20% xylitol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 30
Study: 7737135

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CP) treatment (50-200 mg/day)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CP) treatment (high doses)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sister chromatid exchange (SCE) test
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (n=11)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Patients without chemotherapy (n=5)
Number of subjects: 14
Study: 2407003

Group type: EXPERIMENTAL
Intervention: Prednisone (PRED) therapy
Number of subjects: 67

Group type: COMPARATOR
Intervention: No Prednisone (NOPRED) therapy
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 67
Study: 34415

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine (H1-receptor blocker)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Cimetidine (H2-receptor blocker)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine and Cimetidine (both intravenous)
Number of subjects: 4
Study: 31274710

Group type: EXPERIMENTAL
Intervention: Complete internal limiting membrane peeling (CP)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Fovea‐sparing internal limiting membrane peeling (FSP)
Number of subjects: 46
Study: 31298350

Group type: EXPERIMENTAL
Intervention: Recombinant human basic fibroblast growth factor combined with compound polymyxin B ointment and local application of insulin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Compound polymyxin B ointment
Number of subjects: 80
Study: 28525471

Group type: EXPERIMENTAL
Intervention: Discover arthroplasty
Number of subjects: 105

Group type: COMPARATOR
Intervention: ACDF (anterior cervical discectomy and fusion)
Number of subjects: 105
Study: 25849681

Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nitroglycerine infusion (NTG group)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 20
Study: 23317314

Group type: EXPERIMENTAL
Intervention: Nurse practitioner follow-up intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard model of follow-up care
Number of subjects: 200
Study: 21786523

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 95
Study: 19452097

Group type: EXPERIMENTAL
Intervention: Combined weight-bearing and non-weight-bearing (water) exercise program (E)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 125
Study: 17427617

Group type: EXPERIMENTAL
Intervention: Enteric-coated peppermint oil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination product of peppermint oil and caraway oil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical application of peppermint oil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peppermint oil via enema
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Commonly recommended dosage of peppermint oil
Number of subjects: 0
Study: 15584814

Group type: EXPERIMENTAL
Intervention: Tasks with more complex or less familiar rules
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimulus repetitions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Task-switching experiments
Number of subjects: 0
Study: 11747323

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg daily
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Raloxifene 600 mg daily
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 9010041

Group type: EXPERIMENTAL
Intervention: 2 mg ibandronate
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: 4 mg ibandronate
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: 6 mg ibandronate
Number of subjects: 147
Study: 8343314

Group type: EXPERIMENTAL
Intervention: Aspirin (150 mg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Previous aspirin use
Number of subjects: 200
Study: 3511406

Group type: EXPERIMENTAL
Intervention: Citicoline treatment
Number of subjects: 58
Study: 30894560

Group type: EXPERIMENTAL
Intervention: 40 g high amylose RS2
Number of subjects: 19

Group type: COMPARATOR
Intervention: Energy-matched control starch
Number of subjects: 19
Study: 28535275

Group type: EXPERIMENTAL
Intervention: Inverse odds of sampling weights
Number of subjects: 0
Study: 26269240

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 24140455

Group type: EXPERIMENTAL
Intervention: Postpartum specific intervention designed to address concerns about mood, stress and weight using cognitive‐behavioral techniques
Number of subjects: 300

Group type: COMPARATOR
Intervention: Support-only condition designed to control for time and attention
Number of subjects: 300
Study: 21609524

Group type: EXPERIMENTAL
Intervention: TIMI ≤ 2 group (n = 43)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: TIMI 3 group (n = 43)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group (n = 43)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Both vWF at admission and vWF at the beginning of PCI
Number of subjects: 129
Study: 19329015

Group type: EXPERIMENTAL
Intervention: Epidural infusion of 0.125% bupivacaine with 20 microg/kg/hr midazolam (Group BM)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Epidural infusion of 0.125% bupivacaine alone (Group B)
Number of subjects: 44
Study: 17015404

Group type: EXPERIMENTAL
Intervention: Multislice computed tomography (CT) for the identification and quantification of aortic valvular stenosis (AS)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Echocardiography for measuring the aortic valvular area (AVA)
Number of subjects: 107
Study: 15026091

Group type: EXPERIMENTAL
Intervention: Reinforcement-based procedures
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Behavior severity
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Rater experience
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Behavioral function
Number of subjects: 120
Study: 12065109

Group type: EXPERIMENTAL
Intervention: PTA followed by EVBT
Number of subjects: 113
Study: 9689267

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.17 mg/kg i.v.
Number of subjects: 95

Group type: COMPARATOR
Intervention: Droperidol 0.02 mg/kg i.v.
Number of subjects: 95
Study: 7722565

Group type: EXPERIMENTAL
Intervention: Rehabilitation
Number of subjects: 63
Study: 2603894

Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ofloxacin and Doxycycline
Number of subjects: 60
Study: 1198232

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2) tablets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desamino-oxy-tocin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous oxytocin after amniotomy
Number of subjects: 0
Study: 30170687

Group type: EXPERIMENTAL
Intervention: TAP block with 0.25% bupivacaine (40mL total)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: TAP block with 0.25% bupivacaine + 1/100,000 epinephrine (40mL total)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 28148296

Group type: EXPERIMENTAL
Intervention: Serious game (n=32)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: E-module (n=34)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Historical control group (n=37)
Number of subjects: 103
Study: 25600085

Group type: COMPARATOR
Intervention: 4 × 6 nmol Cat‐PAD
Number of subjects: 0

Group type: COMPARATOR
Intervention: 8 × 3 nmol Cat‐PAD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23221898

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT) with sodium valproate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Electroconvulsive therapy (ECT) without sodium valproate
Number of subjects: 40
Study: 21499923

Group type: EXPERIMENTAL
Intervention: Training in SINERGIA VR simulator
Number of subjects: 42

Group type: COMPARATOR
Intervention: Pre-training tests of novices
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Post-training tests of novices
Number of subjects: 42
Study: 19369887

Group type: EXPERIMENTAL
Intervention: Leeds Multiple Sclerosis Quality of Life Scale (LMSQoL)
Number of subjects: 69
Study: 16442464

Group type: EXPERIMENTAL
Intervention: Patient education program for hypoglycemia (intervention group)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Conventional patient education on hypoglycemia (control group)
Number of subjects: 207
Study: 15569893

Group type: EXPERIMENTAL
Intervention: Comorbid anxiety disorders
Number of subjects: 500
Study: 10815116

Group type: EXPERIMENTAL
Intervention: Imipramine (up to 300 mg/d)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: CBT plus imipramine
Number of subjects: 312

Group type: COMPARATOR
Intervention: CBT plus placebo
Number of subjects: 312

Group type: COMPARATOR
Intervention: CBT alone
Number of subjects: 312

Group type: COMPARATOR
Intervention: Imipramine alone
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: CBT combined with imipramine
Number of subjects: 312
Study: 8839505

Group type: EXPERIMENTAL
Intervention: High-fruit and -vegetable diets (approximately 16 mg/d carotenoids)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High-carotenoid diet with additional broccoli (205 g/d) for 5 days
Number of subjects: 36

Group type: COMPARATOR
Intervention: Basic high-carotenoid diet alone
Number of subjects: 36
Study: 1530752

Group type: EXPERIMENTAL
Intervention: Deep anesthesia with high doses of sufentanil
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lighter anesthesia with halothane and morphine
Number of subjects: 30
Study: 6331157

Group type: EXPERIMENTAL
Intervention: Enalapril (MK-421, 10 to 20 mg bid)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ, 25 to 50 mg bid)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Combined therapy (MK-421 + HCTZ)
Number of subjects: 39
Study: 31552537

Group type: EXPERIMENTAL
Intervention: Early post-operative ambulation (EA, n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Flat bed rest for 48 hours (BR, n=30)
Number of subjects: 60
Study: 31429896

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 28633669

Group type: EXPERIMENTAL
Intervention: Program A (10 exercises recommended for general LBP)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Program B (4 exercises designed specifically to improve LT muscular endurance)
Number of subjects: 39
Study: 25945019

Group type: EXPERIMENTAL
Intervention: 14 d moxifloxacin‐based sequential therapy (MOX‐ST group)
Number of subjects: 161

Group type: COMPARATOR
Intervention: 14 d clarithromycin‐based sequential therapy (CLA‐ST group)
Number of subjects: 161
Study: 23425374

Group type: EXPERIMENTAL
Intervention: Nurse-led psycho-education program
Number of subjects: 96

Group type: COMPARATOR
Intervention: Usual outpatient care
Number of subjects: 96
Study: 22133942

Group type: EXPERIMENTAL
Intervention: Flowable resin
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional hybrid resin
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Pumice prophylaxis
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Immediate post-placement saliva sample
Number of subjects: 22
Study: 19359326

Group type: EXPERIMENTAL
Intervention: Chronic Disease Self‐Management Programme (CDSMP) for 6 weeks; usual care included regular checkups at an outpatient clinic.
Number of subjects: 317

Group type: COMPARATOR
Intervention: Usual care (control group) consisting of regular checkups at an outpatient clinic.
Number of subjects: 317
Study: 17075320

Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy (29 patients)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control (29 patients)
Number of subjects: 58
Study: 15006114

Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasonography
Number of subjects: 54
Study: 10848740

Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment (50 microg g‐1) applied immediately before irradiation
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Calcipotriol cream (50 microg g‐1) applied immediately before irradiation
Number of subjects: 37

Group type: COMPARATOR
Intervention: Vehicle control (untreated area)
Number of subjects: 37
Study: 9358548

Group type: EXPERIMENTAL
Intervention: Chinchilli Metric
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: f1
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Rescigno Index (exponent = 3)
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Rescigno Index (exponent = 1)
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Rescigno Index (exponent = 1/3)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Typical criteria (AUC and Cmax)
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Chinchilli Metric and f1
Number of subjects: 390
Study: 1563426

Group type: EXPERIMENTAL
Intervention: Paraffin-methylcellulose emulsion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diluted iodine solution or barium suspension
Number of subjects: 0
Study: 3908514

Group type: EXPERIMENTAL
Intervention: Evening primrose oil (2 or 4 gm in children, 6 or 8 gm in adults)
Number of subjects: 123
Study: 3675669

Group type: EXPERIMENTAL
Intervention: Pasteurized antithrombin III concentrate Kybernin HS/P
Number of subjects: 13
Study: 28726550

Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study: 27663358

Group type: EXPERIMENTAL
Intervention: Behavioral intervention (informing patients of a pharmacy‐based opioid disposal program)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Standard opioid prescription
Number of subjects: 79
Study: 25514556

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (high HBsAg levels)
Number of subjects: 48
Study: 22589423

Group type: EXPERIMENTAL
Intervention: 42 mg transdermal nicotine
Number of subjects: 87
Study: 20642661

Group type: COMPARATOR
Intervention: Bupivacaine alone (Group B)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Bupivacaine with fentanyl (Group BF)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Bupivacaine with clonidine (Group BC)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Bupivacaine with clonidine and fentanyl (Group BCF)
Number of subjects: 65
Study: 18358260

Group type: EXPERIMENTAL
Intervention: Look AHEAD lifestyle intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program (DPP) lifestyle intervention
Number of subjects: 0
Study: 16808801

Group type: EXPERIMENTAL
Intervention: Amelogenin proteins (Xelma)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Propylene glycol alginate 7%
Number of subjects: 123
Study: 12952566

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) rechallenge
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil plus mitomycin C (MMC)
Number of subjects: 613
Study: 11012052

Group type: EXPERIMENTAL
Intervention: Interspace cage and local autograft
Number of subjects: 54

Group type: COMPARATOR
Intervention: Iliac crest graft fusion
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Interspace cage placement (one-level)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Interspace cage placement (one or both levels)
Number of subjects: 54
Study: 8672383

Group type: EXPERIMENTAL
Intervention: 0.25% ropivacaine
Number of subjects: 104

Group type: COMPARATOR
Intervention: 0.25% bupivacaine
Number of subjects: 104
Study: 1523568

Group type: EXPERIMENTAL
Intervention: Outpatient treatment
Number of subjects: 325

Group type: COMPARATOR
Intervention: Hospital treatment
Number of subjects: 325
Study: 6489697

Group type: EXPERIMENTAL
Intervention: Taurocholate (10 mM) at pH 1.1
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Taurocholate (10 mM) at pH 7.0
Number of subjects: 5

Group type: COMPARATOR
Intervention: Citrate buffer alone
Number of subjects: 5

Group type: COMPARATOR
Intervention: HCl control solution (200 ml of 100 mM HCl)
Number of subjects: 5
Study: 31733767

Group type: EXPERIMENTAL
Intervention: High velocity low amplitude manipulation of the TLJ
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham (basic touch)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (laying supine on a plinth)
Number of subjects: 21
Study: 29972001

Group type: EXPERIMENTAL
Intervention: RT and intradermal needling (group A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: RT and acupuncture (group B)
Number of subjects: 120

Group type: COMPARATOR
Intervention: RT alone (group C)
Number of subjects: 120
Study: 27833919

Group type: EXPERIMENTAL
Intervention: Supervised walking exercises on the treadmill (n = 24)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Resistance exercises of lower limbs (n = 26)
Number of subjects: 50
Study: 24535349

Group type: EXPERIMENTAL
Intervention: Two-step etch-and-rinse adhesive α
Number of subjects: 50

Group type: COMPARATOR
Intervention: One-step self-etch adhesive β
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both adhesives
Number of subjects: 50
Study: 22682750

Group type: EXPERIMENTAL
Intervention: 4 months of neo-adjuvant androgen deprivation (NAD) before radiation therapy (RT)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: 8 months of neo-adjuvant androgen deprivation (NAD) before radiation therapy (RT)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Neo-adjuvant androgen deprivation (NAD) in addition to radiation therapy
Number of subjects: 276
Study: 20302872

Group type: EXPERIMENTAL
Intervention: Performance-based stressor task
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Social rejection stressor task
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control group (low psychopathic traits)
Number of subjects: 145
Study: 18569687

Group type: EXPERIMENTAL
Intervention: Performed actions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observed actions
Number of subjects: 0
Study: 16048922

Group type: EXPERIMENTAL
Intervention: Rifampin orally at 10 mg/kg of body weight and streptomycin intramuscularly at 15 mg/kg of body weight daily for 2 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Rifampin and streptomycin for 4 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Rifampin and streptomycin for 8 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Rifampin and streptomycin for 12 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: No antibiotic treatment
Number of subjects: 10
Study: 11350535

Group type: EXPERIMENTAL
Intervention: Minimization allocation method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional analysis following minimization
Number of subjects: 0
Study: 9782811

Group type: EXPERIMENTAL
Intervention: Biofeedback/relaxation training
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 119

Group type: COMPARATOR
Intervention: Educational/attention control program
Number of subjects: 119
Study: 7846337

Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone (500 mg)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Intravenous normal saline (control)
Number of subjects: 98
Study: 3072420

Group type: EXPERIMENTAL
Intervention: 75 mg captopril once daily
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 37.5 mg captopril twice daily
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 25 mg captopril three times daily
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 30967405

Group type: EXPERIMENTAL
Intervention: ACTonPain guided
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: ACTonPain unguided
Number of subjects: 302

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 302
Study: 27222939

Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT)
Number of subjects: 3640

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 3640
Study: 24978931

Group type: EXPERIMENTAL
Intervention: Foam rubber exercise group (n = 32)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Stable surface exercise group (n = 31)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (n = 30)
Number of subjects: 93
Study: 23712073

Group type: EXPERIMENTAL
Intervention: Cognitive Restructuring and Imagery Modification (CRIM)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Waitlist control (WL)
Number of subjects: 34
Study: 21354935

Group type: EXPERIMENTAL
Intervention: Pelvic methotrexate (MTX) injection via the posterior fornix + mifepristone + traditional Chinese medicine
Number of subjects: 96

Group type: COMPARATOR
Intervention: Intramuscular MTX injection + mifepristone + traditional Chinese medicine
Number of subjects: 96

Group type: COMPARATOR
Intervention: Mifepristone + traditional Chinese medicine
Number of subjects: 96
Study: 19365399

Group type: EXPERIMENTAL
Intervention: escitalopram (serotonin reuptake inhibitor)
Number of subjects: 760

Group type: EXPERIMENTAL
Intervention: nortriptyline (norepinephrine reuptake inhibitor)
Number of subjects: 760

Group type: EXPERIMENTAL
Intervention: both escitalopram and nortriptyline
Number of subjects: 760
Study: 17455472

Group type: EXPERIMENTAL
Intervention: Shenfu injection (SF)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150